NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 51 filers reported holding NEUROCRINE BIOSCIENCES INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $33,829,158,000 | +16.8% | 25,450,000 | +18.6% | 0.01% | +7.7% |
| Q1 2021 | $28,956,213,000 | -2.9% | 21,450,000 | 0.0% | 0.01% | -7.1% |
| Q4 2020 | $29,821,721,000 | +27.6% | 21,450,000 | +26.5% | 0.01% | +7.7% |
| Q3 2020 | $23,362,863,000 | +0.9% | 16,950,000 | +21.5% | 0.01% | -7.1% |
| Q2 2020 | $23,155,884,000 | +10.9% | 13,950,000 | -14.7% | 0.01% | -6.7% |
| Q1 2020 | $20,871,593,000 | -16.5% | 16,350,000 | 0.0% | 0.02% | 0.0% |
| Q4 2019 | $25,001,603,000 | +5.0% | 16,350,000 | -5.8% | 0.02% | -6.2% |
| Q3 2019 | $23,803,333,000 | +4.0% | 17,350,000 | 0.0% | 0.02% | 0.0% |
| Q2 2019 | $22,878,057,000 | -2.6% | 17,350,000 | 0.0% | 0.02% | -5.9% |
| Q1 2019 | $23,492,768,000 | +2.1% | 17,350,000 | -10.3% | 0.02% | -15.0% |
| Q4 2018 | $23,000,378,000 | -50.7% | 19,350,000 | -29.3% | 0.02% | -42.9% |
| Q3 2018 | $46,673,322,000 | -8.3% | 27,350,000 | -22.6% | 0.04% | -10.3% |
| Q2 2018 | $50,914,605,000 | – | 35,350,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Myriad Asset Management Ltd. | 17,500,000 | $29,890,000 | 4.31% |
| SSI INVESTMENT MANAGEMENT LLC | 8,987,000 | $15,319,000 | 1.18% |
| CSS LLC/IL | 14,955,000 | $25,561,000 | 1.09% |
| SHENKMAN CAPITAL MANAGEMENT INC | 3,983,000 | $6,799,000 | 0.82% |
| Verition Fund Management LLC | 6,425,000 | $10,968,000 | 0.39% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 9,495,000 | $16,214,000 | 0.33% |
| MACKAY SHIELDS LLC | 21,609,000 | $36,877,000 | 0.28% |
| WOLVERINE ASSET MANAGEMENT LLC | 12,776,000 | $21,819,000 | 0.25% |
| Calamos Advisors LLC | 24,100,000 | $41,405,000 | 0.23% |
| OAKTREE CAPITAL MANAGEMENT LP | 8,895,000 | $15,184,000 | 0.20% |